DPC-681
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


DPC-681
Description :
DPC-681 is a potent and selective inhibitor of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM. IC50 value: 4 - 40 nM [1] Target: HIV protease in vitro: DPC 681 is extremely potent inhibitor of wild-type HIV-1. When all of the HIV-1 strains tested are considered, the average concentrations required for 90% inhibition of replication were 7.3 ± 3.4 for DPC 681. DPC 681 shows no loss in potency toward recombinant mutant HIVs with the D30N mutation and a fivefold or smaller loss in potency toward mutant variants with three to five amino acid substitutions. [1] in vivo: The total body clearance (CL) of DPC 681 in dogs was high (1.8 liter/h/kg) equaling hepatic blood flow for this species (1.8 liter/h/kg) . After an oral dosing, the Cmax increased ninefold between the 10- and 30-mg/kg DPC 681 dose groups. Bioavailability also increased between the 10- and 30-mg/kg dose groups (18.3 and 78.1%, respectively) . These data suggest that hepatic extraction (first-pass effect) can be saturated in the dog. [1]CAS Number :
[284661-68-3]Product Name Alternative :
DPH-153893UNSPSC :
12352005Target :
HIV; HIV ProteaseType :
Reference compoundRelated Pathways :
Anti-infection; Metabolic Enzyme/ProteaseApplications :
COVID-19-anti-virusField of Research :
InfectionAssay Protocol :
https://www.medchemexpress.com/DPC-681.htmlPurity :
99.72Solubility :
DMSO : 100 mg/mL (ultrasonic)Smiles :
O=S(C1=CC(N)=CC=C1)(N(C[C@@H](O)[C@H](CC2=CC=CC=C2)NC([C@H](C(C)(C)C)NC(CNCC3=CC=CC(F)=C3)=O)=O)CC(C)C)=OMolecular Formula :
C35H48FN5O5SMolecular Weight :
669.85References & Citations :
[1]Kaltenbach RF 3rd, et al. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45 (11) :3021-8.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
Phase 1Isoform :
HIV-1

